NCT05955651

Brief Summary

The Aim of the study is to determine endometrial/myometrial spillage during total laparoscopic hysterectomy with manual morcellation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 13, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 21, 2023

Completed
11 days until next milestone

Study Start

First participant enrolled

August 1, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 10, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 10, 2025

Completed
Last Updated

August 5, 2025

Status Verified

August 1, 2025

Enrollment Period

1.9 years

First QC Date

July 13, 2023

Last Update Submit

August 1, 2025

Conditions

Keywords

HysterectomyPelvic washingsMyometrial cell spillageFibroids

Outcome Measures

Primary Outcomes (1)

  • Detection of myometrial cell spillage in peritoneal washing

    To evaluate potential cell spillage from morcellated tissue, the 3 peritoneal washings collected will be sent to cytology lab to be examined for the presence of smooth muscle cells

    Pelvic washing samples will be sent the pathology lab to be examined within 2 days of the surgery.

Secondary Outcomes (1)

  • Timing of myometrial cell spillage during hysterectomy

    Pelvic washing samples will be sent the pathology lab to be examined within 2 days of the surgery.

Study Arms (1)

Pelvic washings

Three Samples of peritoneal washings will be collected and send to pathology. looking for myometrial cell spillage at three designated points in surgery. 1st before hysterectomy, 2nd after hysterectomy, and 3rd after morcellation and extraction of the uterus out of the abdominal cavity.

Diagnostic Test: Peritoneal washings

Interventions

Peritoneal washingsDIAGNOSTIC_TEST

Peritoneal washing will be done at designated point in the surgical procedure. one hundred cc of normal saline, will be used to irrigate the peritoneal cavity. Samples of the fluid will be collected, with the goal to collect as much fluid as possible for the study, with minimum of 60 cc should be collected. Samples will be sent to the pathology lab. 1. First washing will be collected after obtaining entry into the peritoneal cavity with placement of the first laparoscopic trocar, before any manipulation of the uterus. 2. Second washing will be done after the hysterectomy and containment of the uterus in the bag. 3. Third washing will be collected after scalpel morcellation of the uterus in the containment bag, extraction and closure of the vaginal cuff.

Pelvic washings

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women needing minimally invasive hysterectomy for benign conditions, 18 years and older.

You may qualify if:

  • Women undergoing minimally invasive Laparoscopic / Robotic hysterectomy for presumably benign conditions such as (fibroids, adenomyosis, endometriosis, pelvic organ prolapse, abnormal uterine bleeding)
  • Large size uterus measuring more than 10 cm on US requiring cold knife morcellation within the Alexis containment bag, surgery will be done by designated surgeon at UTMB from 08/01/2023 to 08/01/2024.
  • Women 18 years and older
  • Subjects must be able to provide consents.
  • Normal endometrial biopsy.
  • Normal cervical cancer screening

You may not qualify if:

  • Known Gynecological malignancy.
  • Endometrial biopsy with endometrial intraepithelial hyperplasia.
  • History of exposure to pelvic radiation
  • Post-menopausal patients
  • Emergency hysterectomy
  • TDC patients
  • Patient less than 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Medical branch

Galveston, Texas, 77555, United States

Location

MeSH Terms

Conditions

Leiomyoma

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 13, 2023

First Posted

July 21, 2023

Study Start

August 1, 2023

Primary Completion

June 10, 2025

Study Completion

June 10, 2025

Last Updated

August 5, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations